✦ LIBER ✦

Addition Of Bortezemib To High Dose Melphalan Does Not Improve Response Rate Or Progression-Free Survival

✍ Scribed by M. Sharma; M.H. Qazilbash; C.M. Hosing; P.F. Thall; F.L. Mendoza; E. Han; M. Wang; J. Shah; A.M. Alousi; P. Anderlini; P. Kebriaei; I.F. Khouri; U.R. Popat; M. de Lima; R.E. Champlin; S.A. Giralt

Book ID: 116281359
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 80 KB
Volume: 16
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2009.12.147

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The addition of high-dose tamoxifen to s

The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma

✍ Antony Michalski; Eric Bouffet; Roger E. Taylor; Darren Hargrave; David Walker; 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 223 KB

Folinic acid dose and addition of levami

Folinic acid dose and addition of levamisole does not seem to improve survival or recurrence rates in people treated with adjuvant fluorouracil and folinic acid for colorectal cancer

✍ Philippe Rougier 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 258 KB

Final Outcomes of Escalated Melphalan 28

Final Outcomes of Escalated Melphalan 280 mg/m2 Prior to Autologous Hematopoietic Cell Transplantation for Multiple Myeloma (MM): High CR+VGPR Rate Does Not Translate Into Improved Survival

✍ Randhawa, Jasleen K.; Hari, Parameswaran N.; Reece, Donna E.; Vesole, David 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Adding high-dose tamoxifen to CHOP does

Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial

✍ A A Ezzat; E M Ibrahim; R K Stuart; D Ajarim; S Bazarbashi; M O El-Foudeh; M Rah 📂 Article 📅 2000 🏛 Springer US 🌐 English ⚖ 762 KB